Wright Medical 10-Q 7 Aug 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 29, 2014	Aug. 01, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	29-Jun-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Trading Symbol	'TRNX	'
Entity Registrant Name	'Tornier N.V.	'
Entity Central Index Key	'0001492658	'
Current Fiscal Year End Date	'--12-29	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	48,909,656

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Jun. 29, 2014	Dec. 29, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$31,771	$56,784
Accounts receivable (net of allowance of $5,393 and $5,080, respectively)	58,644	55,555
Inventories	95,560	87,011
Deferred income taxes	5,551	5,601
Prepaid taxes	14,461	14,667
Prepaid expenses	4,141	3,151
Other current assets	6,674	3,756
Total current assets	216,802	226,525
Instruments, net	68,943	63,055
Property, plant and equipment, net	44,419	43,494
Goodwill	252,974	251,540
Intangible assets, net	108,720	117,608
Deferred income taxes	660	660
Other assets	1,448	2,544
Total assets	693,966	705,426
Current liabilities:	'	'
Short-term borrowings and current portion of long-term debt	1,364	1,438
Accounts payable	21,149	17,326
Accrued liabilities	53,120	50,714
Income taxes payable	1,354	397
Contingent consideration, current	8,667	6,428
Deferred income taxes	14	13
Total current liabilities	85,668	76,316
Long-term debt	67,948	67,643
Deferred income taxes	21,255	21,489
Contingent consideration, long-term	148	6,528
Other non-current liabilities	7,635	7,642
Total liabilities	182,654	179,618
Shareholders' equity:	'	'
Ordinary shares, €0.03 par value; authorized 175,000,000; issued and outstanding 48,797,382 and 48,508,612 at June 29, 2014 and December 29, 2013, respectively	1,932	1,921
Additional paid-in capital	776,143	769,466
Accumulated deficit	-287,841	-272,158
Accumulated other comprehensive income	21,078	26,579
Total shareholders' equity	511,312	525,808
Total liabilities and shareholders' equity	$693,966	$705,426

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical)	Jun. 29, 2014	Jun. 29, 2014	Dec. 29, 2013	Dec. 29, 2013
In Thousands, except Share data, unless otherwise specified	USD ($)	EUR (€)	USD ($)	EUR (€)
Statement Of Financial Position [Abstract]	'	'	'	'
Accounts receivable, allowance	$5,393	'	$5,080	'
Ordinary shares, par value	'	€ 0.03	'	€ 0.03
Ordinary shares, authorized	175,000,000	175,000,000	175,000,000	175,000,000
Ordinary shares, issued	48,797,382	48,797,382	48,508,612	48,508,612
Ordinary shares, outstanding	48,797,382	48,797,382	48,508,612	48,508,612

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (unaudited) (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 29, 2014	Jun. 30, 2013	Jun. 29, 2014	Jun. 30, 2013
Income Statement [Abstract]	'	'	'	'
Revenue	$86,850	$78,135	$175,875	$160,820
Cost of goods sold	21,227	22,309	43,691	45,933
Gross profit	65,623	55,826	132,184	114,887
Operating expenses:	'	'	'	'
Selling, general and administrative	62,504	51,467	121,352	103,603
Research and development	6,068	5,543	11,790	11,725
Amortization of intangible assets	4,320	3,784	8,654	7,621
Special charges	686	3,408	3,372	4,927
Total operating expenses	73,578	64,202	145,168	127,876
Operating loss	-7,955	-8,376	-12,984	-12,989
Other income (expense):	'	'	'	'
Interest income	40	57	108	96
Interest expense	-1,365	-2,037	-2,714	-4,255
Foreign currency transaction loss	-214	-705	-43	-786
Loss on extinguishment of debt	'	-1,127	'	-1,127
Other non-operating income	7	71	9	88
Loss before income taxes	-9,487	-12,117	-15,624	-18,973
Income tax expense	-961	-420	-61	-462
Consolidated net loss	($10,448)	($12,537)	($15,685)	($19,435)
Net loss per share:	'	'	'	'
Basic and diluted	($0.21)	($0.28)	($0.32)	($0.45)
Weighted average shares outstanding:	'	'	'	'
Basic and diluted	48,612	45,004	48,568	43,379

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Loss (unaudited) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 29, 2014	Jun. 30, 2013	Jun. 29, 2014	Jun. 30, 2013
Statement Of Income And Comprehensive Income [Abstract]	'	'	'	'
Consolidated net loss	($10,448)	($12,537)	($15,685)	($19,435)
Foreign currency translation adjustments	-3,818	6,203	-5,501	73
Comprehensive loss	($14,266)	($6,334)	($21,186)	($19,362)

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (unaudited) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 29, 2014	Jun. 30, 2013
Cash flows from operating activities:	'	'
Consolidated net loss	($15,685)	($19,435)
Adjustments to reconcile consolidated net loss to cash provided by operating activities:	'	'
Depreciation and amortization	20,262	17,781
Non-cash foreign currency loss	39	786
Deferred income taxes	-2,435	2,328
Tax benefit from reversal of valuation allowance	-146	-540
Share-based compensation	4,521	3,069
Non-cash interest expense and discount amortization	354	566
Inventory obsolescence	5,678	4,179
Loss on extinguishment of debt	'	1,127
Acquired inventory step up	420	3,676
Other non-cash items affecting earnings	326	1,306
Changes in operating assets and liabilities, net of acquisitions:	'	'
Accounts receivable	-3,219	1,345
Inventories	-15,326	-2,060
Accounts payable and accruals	8,167	5,546
Other current assets and liabilities	-3,347	-2,061
Other non-current assets and liabilities	496	128
Net cash provided by operating activities	105	17,741
Cash flows from investing activities:	'	'
Acquisition-related cash payments	-7,602	-5,672
Purchases of intangible assets	-20	-451
Additions of instruments	-14,535	-12,450
Purchases of property, plant and equipment	-4,880	-4,778
Net cash used in investing activities	-27,037	-23,351
Cash flows from financing activities:	'	'
Change in short-term debt	'	-1,000
Repayments of long-term debt	-563	-53,329
Proceeds from long-term debt	477	'
Deferred financing costs	'	-53
Issuance of ordinary shares from stock option exercises	2,067	9,386
Proceeds from issuance of ordinary shares	129	78,870
Net cash provided by financing activities	2,110	33,874
Effect of exchange rate changes on cash and cash equivalents	-191	-657
(Decrease) increase in cash and cash equivalents	-25,013	27,607
Cash and cash equivalents:	'	'
Beginning of period	56,784	31,108
End of period	31,771	58,715
Non-cash investing and financing activities:	'	'
Fixed assets acquired pursuant to capital lease	'	13
Capitalized software development costs	'	$1,516

Business_Description

Business Description	6 Months Ended
	Jun. 29, 2014
Accounting Policies [Abstract]	'
Business Description	'
	1. Business Description
	Tornier N.V. (Tornier or the Company) is a global medical device company focused on providing solutions to surgeons that treat musculoskeletal injuries and disorders of the shoulder, elbow, wrist, hand, ankle and foot, which are collectively referred to as “extremity joints.” The Company sells to this surgeon base a broad line of joint replacement, trauma, sports medicine and biologic products to treat extremity joints. In certain international markets, the Company also offers joint replacement products for the hip and knee.
	Tornier’s global corporate headquarters are located in Amsterdam, the Netherlands. The Company also has significant operations located in Bloomington, Minnesota (U.S. headquarters, sales, marketing and distribution and administration), Grenoble, France (OUS headquarters, manufacturing and research and development), Macroom, Ireland (manufacturing), Warsaw, Indiana (research and development) and Medina, Ohio (marketing, research and development). In addition, the Company conducts local sales and distribution activities across 13 sales offices throughout Europe, Asia, Australia and Canada.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 29, 2014
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	2. Summary of Significant Accounting Policies
	Consolidation
	The consolidated financial statements include the accounts of the Company and all of its wholly and majority owned subsidiaries. In consolidation, all material intercompany accounts and transactions are eliminated.
	Use of Estimates
	The consolidated financial statements are prepared in conformity with United States generally accepted accounting principles (U.S. GAAP) and include amounts that are based on management’s best estimates and judgments. Actual results could differ from those estimates.
	Basis of Presentation
	The Company’s fiscal year-end is generally determined on a 52-week basis consisting of four 13-week quarters and always falls on the Sunday nearest to December 31.
	In the opinion of the Company’s management, the unaudited interim financial statements have been prepared on the same basis as the audited financial statements and include all adjustments, consisting of normal recurring accruals, necessary for the fair presentation of the Company’s interim results. The results of operations for any interim period are not indicative of results for the full fiscal year.
	All amounts are presented in U.S. Dollar (“$”), except where expressly stated as being in other currencies, e.g. Euros (“€”).
	Seasonality
	The Company’s business is somewhat seasonal in nature, as many of its products are used in elective procedures, which typically decline during the summer months and can increase at the end of the year once annual deductibles have been met on health insurance plans.
	Recently Issued Accounting Pronouncements
	In July 2013, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2013-11, Income Taxes (ASC Topic 740), Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists. The ASU requires entities to present unrecognized tax benefits as a decrease in a net operating loss, similar to tax loss or tax credit carryforward if certain criteria are met. The standard clarifies presentation requirements for unrecognized tax benefits but will not alter the way in which entities assess deferred tax assets for realizability. The guidance is effective for the fiscal year, and interim periods within that fiscal year, beginning after December 15, 2013. The Company adopted this guidance beginning in the first quarter of 2014. The impact of adoption was not material.
	In March 2013, the FASB issued ASU 2013-05, Foreign Currency Matters (ASC Topic 830), Parent’s Accounting for the Cumulative Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity. The ASU requires entities to release cumulative translation adjustments to earnings when an entity ceases to have a controlling financial interest in a subsidiary or group of assets within a consolidated foreign entity and the sale or transfer results in the complete or substantially complete liquidation of the foreign entity. The ASU is effective for the fiscal year, and interim periods within that fiscal year, beginning after December 15, 2013 and is to be applied prospectively. The Company adopted this guidance in the first quarter of 2014. The impact of adoption was not material.
	In February 2013, the FASB issued ASU 2013-04, Liabilities (ASC Topic 405), Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation is Fixed at the Reporting Date. The ASU requires an entity that is jointly and severally liable to measure the obligation as the sum of the amount the entity has agreed with co-obligors to pay and any additional amount it expects to pay on behalf of one or more co-obligors. The amendment is effective for the fiscal year, and interim periods within that fiscal year, beginning after December 15, 2013 and should be applied retrospectively. The Company adopted this guidance beginning in the first quarter of 2014. The impact of adoption was not material.
	In April 2014, the FASB issued ASU 2014-08, Presentation of Financial Statements (ASC Topic 205) and Property, Plant, and Equipment (ASC Topic 360)—Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity. ASU 2014-08 provides new guidance related to the definition of a discontinued operation and requires new disclosures of both discontinued operations and certain other disposals that do not meet the definition of a discontinued operation. This new guidance is effective for annual periods beginning on or after December 15, 2014 and interim periods within those years. Beginning in 2015, the Company will adopt the new guidance, as applicable, to future disposals of components or classifications as held for sale.
	In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers issued as a new topic, ASC 606. ASU 2014-09 provides new guidance related to how an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, ASU 2014-08 specifies new accounting for costs associated with obtaining or fulfilling contracts with customers and expands the required disclosures related to revenue and cash flows from contracts with customers. This new guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016, and can be adopted either retrospectively to each prior reporting period presented or as a cumulative-effect adjustment as of the date of adoption, with early application not permitted. The Company is currently determining its implementation approach and assessing the impact on its consolidated financial statements and related disclosures.

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments	6 Months Ended
	Jun. 29, 2014
Fair Value Disclosures [Abstract]	'
Fair Value of Financial Instruments	'
	3. Fair Value of Financial Instruments
	The Company applies ASC Topic 820, which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. The Company measures certain assets and liabilities at fair value on a recurring or non-recurring basis. U.S. GAAP requires fair value measurements to be classified and disclosed in one of the following three categories:
	Level 1—Assets and liabilities with unadjusted, quoted prices listed on active market exchanges.
	Level 2—Assets and liabilities determined using prices for recently traded assets and liabilities with similar underlying terms, as well as directly or indirectly observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.
	Level 3—Assets and liabilities that are not actively traded on a market exchange. This category includes situations where there is little, if any, market activity for the asset or liability. The prices are determined using significant unobservable inputs or valuation techniques.
	A summary of the financial assets and liabilities that are measured at fair value on a recurring basis at June 29, 2014 and December 29, 2013 are as follows:
		June 29, 2014			Quoted Prices in		Significant		Significant
					Active Markets		Other		Unobservable
					(Level 1)		Observable		Inputs (Level 3)
							Inputs (Level 2)
	Cash and cash equivalents	$	31,771		$	31,771	$	—	$	—
	Contingent consideration		(8,815	)		—		—		(8,815	)
	Derivative assets		89			—		89		—
	Total, net	$	23,045		$	31,771	$	89	$	(8,815	)
		December 29, 2013			Quoted Prices in		Significant		Significant
					Active Markets		Other		Unobservable
					(Level 1)		Observable		Inputs (Level 3)
							Inputs (Level 2)
	Cash and cash equivalents	$	56,784		$	56,784	$	—	$	—
	Contingent consideration		(12,956	)		—		—		(12,956	)
	Derivative assets		238			—		238		—
	Total, net	$	44,066		$	56,784	$	238	$	(12,956	)
	As of June 29, 2014 and December 29, 2013, the Company had derivative assets with fair values of $0.1 million and $0.2 million, respectively, with recurring Level 2 fair value measurements. The derivatives are foreign exchange forward contracts and their fair values are based on pricing for similar recently executed transactions. The amount of gain recognized in foreign currency transaction loss for the six months ended June 29, 2014 and June 30, 2013 related to these derivatives is $0.2 million and $0.1 million, respectively.
	Included in Level 3 fair value measurements as of June 29, 2014 is a $5.9 million contingent consideration liability related to potential earn-out payments for the acquisition of OrthoHelix Surgical Designs, Inc. (OrthoHelix) that was completed in October 2012, a $2.3 million contingent consideration liability related to potential earn-out payments for distributor acquisitions in the United States that occurred throughout 2013 and the first six months of 2014, a $0.4 million contingent consideration liability related to potential earn-out payments for the acquisition of the Company’s exclusive distributor in Belgium and Luxembourg that was completed in May 2012, and a $0.2 million contingent consideration liability related to potential earn-out payments related to the acquisition of a distributor in Australia that was completed in 2013. Contingent consideration liabilities are carried at fair value and are included in contingent consideration (short-term and long-term) on the consolidated balance sheets. The contingent consideration liabilities were determined based on discounted cash flow analyses that included revenue estimates and a discount rate, which are considered significant unobservable inputs as of June 29, 2014. The revenue estimates were based on current management expectations for these businesses and the discount rate used was between 8-11% and was based on the Company’s estimated weighted average cost of capital as adjusted for each transaction. To the extent that these assumptions were to change, the fair value of the contingent consideration liabilities could change significantly. Included in interest expense on the consolidated statements of operations for the six months ended June 29, 2014 and June 30, 2013 is $0.3 million and $0.6 million, respectively, related to the accretion of the contingent consideration. There were no transfers between levels during the periods presented.
	Included in Level 3 fair value measurements as of December 29, 2013 is a $10.4 million contingent consideration liability related to potential earnout payments for the acquisition of OrthoHelix that was completed in October 2012, a $1.9 million contingent consideration liability related to potential earn-out payments for distributor acquisitions in the United States that occurred throughout 2013, a $0.5 million contingent consideration liability related to potential earnout payments for the acquisition of the Company’s exclusive distributor in Belgium and Luxembourg that was completed in May 2012 and a $0.2 million contingent consideration liability related to potential earnout payments related to the acquisition of a distributor in Australia that was completed in 2013.
	A rollforward of the Level 3 contingent consideration liabilities, both short and long-term, for the six months ended June 29, 2014 is as follows (in thousands):
	Contingent consideration liability at December 29, 2013	$	12,956
	Additions		1,670
	Fair value adjustments		(312	)
	Settlements		(5,802	)
	Interest accretion		299
	Foreign currency translation		4
	Contingent consideration liability at June 29, 2014	$	8,815
	The Company also has certain assets and liabilities that are measured at fair value on a non-recurring basis. The Company reviews the carrying amount of its long-lived assets other than goodwill for potential impairment whenever events or changes in circumstances indicate that their carrying values may not be recoverable. During the six months ended June 29, 2014 and June 30, 2013, the Company recognized no impairments. During 2013, the Company initiated and completed a facilities consolidation initiative that included the termination of certain facility leases. The termination liability for these leases was determined using a discounted cash flow analysis that included a discount rate assumption, which is based on the credit adjusted risk free interest rate input, and an assumption related to the timing and amount of sublease income. The timing of the sublease income is a significant unobservable input and thus is considered a Level 3 fair value measurement. As of June 29, 2014, the value of this liability was $0.3 million.
	As of June 29, 2014 and December 29, 2013, the Company had short-term and long-term debt of $69.3 million and $69.1 million, respectively, the vast majority of which was variable rate debt. The fair value of the Company’s debt obligations approximates carrying value as a result of its variable rate term and is considered a Level 2 fair value measurement.

Inventories

Inventories	6 Months Ended
	Jun. 29, 2014
Inventory Disclosure [Abstract]	'
Inventories	'
	4. Inventories
	Inventory balances consist of the following (in thousands):
		June 29, 2014		December 29, 2013
	Raw materials	$	7,007	$	6,840
	Work-in-process		13,154		9,171
	Finished goods		75,399		71,000
	Total	$	95,560	$	87,011

Property_Plant_and_Equipment

Property, Plant and Equipment	6 Months Ended
	Jun. 29, 2014
Property Plant And Equipment [Abstract]	'
Property, Plant and Equipment	'
	5. Property, Plant and Equipment
	Property, plant and equipment balances consist of the following (in thousands):
		June 29,			December 29,
		2014			2013
	Land	$	1,651		$	1,886
	Building and improvements		13,646			14,255
	Machinery and equipment		31,771			31,192
	Furniture, fixtures and office equipment		30,522			29,371
	Software		5,399			5,511
	Construction in progress		7,454			5,628
	Property, plant and equipment, gross		90,443			87,843
	Accumulated depreciation		(46,024	)		(44,349	)
	Property, plant and equipment, net	$	44,419		$	43,494

Instruments

Instruments	6 Months Ended
	Jun. 29, 2014
Text Block [Abstract]	'
Instruments	'
	6. Instruments
	Instruments are included in long-term assets on the consolidated balance sheets and consist of the following (in thousands):
		June 29,			December 29,
		2014			2013
	Instruments	$	109,022		$	99,754
	Instruments in process		27,108			23,990
	Accumulated depreciation		(67,187	)		(60,689	)
	Instruments, net	$	68,943		$	63,055

Goodwill_and_Other_Intangible_

Goodwill and Other Intangible Assets	6 Months Ended
	Jun. 29, 2014
Goodwill And Intangible Assets Disclosure [Abstract]	'
Goodwill and Other Intangible Assets	'
	7. Goodwill and Other Intangible Assets
	The following table summarizes the changes in the carrying amount of goodwill (in thousands):
	Balance at December 29, 2013	$	251,540
	Goodwill additions as a result of acquisitions		2,467
	Foreign currency translation		(1,033	)
	Balance at June 29, 2014	$	252,974
	The components of identifiable intangible assets are as follows (in thousands):
		Gross value			Accumulated			Net value
					amortization
	Balances at June 29, 2014
	Intangible assets subject to amortization:
	Developed technology	$	112,657		$	(48,604	)	$	64,053
	Customer relationships		61,085			(32,126	)		28,959
	Licenses		6,831			(4,601	)		2,230
	Other		7,109			(3,455	)		3,654
	Intangible assets not subject to amortization:
	Trade name		9,824			—			9,824
	Total	$	197,506		$	(88,786	)	$	108,720
		Gross value			Accumulated			Net value
					amortization
	Balances at December 29, 2013
	Intangible assets subject to amortization:
	Developed technology	$	112,782		$	(44,161	)	$	68,621
	Customer relationships		61,783			(30,155	)		31,628
	Licenses		6,810			(4,004	)		2,806
	In-process research and development		400			—			400
	Other		6,624			(2,431	)		4,193
	Intangible assets not subject to amortization:
	Trade name		9,960			—			9,960
	Total	$	198,359		$	(80,751	)	$	117,608
	Estimated annual amortization expense for fiscal years ending 2014 through 2018 is as follows (in thousands):
		Amortization expense
	2014	$	17,411
	2015		16,819
	2016		14,479
	2017		13,470
	2018		12,646
	During the six months ended June 29, 2014, the Company acquired intangible assets in the form of non-compete agreements and goodwill in the amounts of $0.2 million and $2.5 million, respectively, related to the acquisition of certain U.S. distributors and independent sales agencies.

ShareBased_Compensation

Share-Based Compensation	6 Months Ended
	Jun. 29, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Share-Based Compensation	'
	8. Share-Based Compensation
	Share-based awards are granted under the Tornier N.V. 2010 Incentive Plan, as amended. This plan allows for the issuance of up to a maximum of 7.7 million ordinary shares in connection with the grant of share-based awards, including stock options, restricted stock units, stock appreciation rights and other types of awards as deemed appropriate. To date, only options to purchase ordinary shares (options) and stock grants in the form of restricted stock units (RSUs) have been awarded under the plan. Both types of awards generally have graded vesting periods of four years and the options generally expire ten years after the grant date. Options are granted with exercise prices equal to the fair value of the Company’s ordinary shares on the date of grant.
	The Company recognizes compensation expense for these awards on a straight-line basis over the vesting period. Share-based compensation expense is included in cost of goods sold, selling, general and administrative expense, and research and development expense on the consolidated statements of operations.
	Below is a summary of the allocation of share-based compensation (in thousands):
		Three months ended					Six months ended
		June 29,			June 30,		June 29,		June 30,
		2014			2013		2014		2013
					(unaudited)				(unaudited)
	Cost of goods sold	$	152		$	120	$	304	$	264
	Selling, general and administrative		2,341			1,180		3,900		2,525
	Research and development		249			136		317		280
	Total	$	2,742		$	1,436	$	4,521	$	3,069
	During the six months ended June 29, 2014, the Company granted options to purchase an aggregate of 20,661 ordinary shares to employees at a weighted average exercise price of $19.66 per share and a weighted average fair value of $8.74 per share. The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model using the following weighted-average assumptions:
		Six months ended
		June 29, 2014
	Risk-free interest rate		1.9	%
	Expected life in years		6
	Expected volatility		45	%
	Expected dividend yield		0	%
	During the six months ended June 29, 2014, the Company granted 20,834 restricted stock units to employees with a weighted average fair value of $19.42 per share. In addition, the Company granted 100,000 performance-accelerated restricted stock units (PARS). The PARS are subject to a graded service-based vesting schedule of 50% vesting after two years, 25% after the third year and 25% after the fourth year, all of which can be accelerated upon the achievement of certain share price targets of the Company’s ordinary shares. PARS are expensed on a straight-line basis over the shorter of the explicit service period related to the service condition or the implicit service period related to the performance condition, based on the probability of meeting the conditions. The grant date weighted average fair value and related calculated vesting period of the PARS was $19.24 and 3.4 years, respectively.

Income_Taxes

Income Taxes	6 Months Ended
	Jun. 29, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	9. Income Taxes
	The Company’s effective tax rate for the six months ended June 29, 2014 was less than 0.1%. During the six months ended June 29, 2014, the Company recognized $0.1 million of income tax expense on pre-tax losses of $15.6 million. The Company recognized $0.6 million of tax expense in certain European jurisdictions during the six months ended June 29, 2014. A tax benefit of $0.5 million was recognized primarily related to the reversal of a reserve for uncertain tax positions. Given the Company’s history of operating losses, the Company does not generally recognize a provision for income taxes in the United States and certain jurisdictions in Europe because it has established a valuation allowance for substantially all of the net deferred tax assets in these jurisdictions. The Company records tax expense or benefit in certain other international jurisdictions where a valuation allowance has not been established. The mix of pre-tax income or loss in these jurisdictions as well as in the jurisdictions in which valuation allowances are established are the primary drivers of the Company’s effective tax rate.
	The Company operates in multiple income tax jurisdictions both inside and outside the United States. Income tax authorities in these jurisdictions regularly perform audits of the Company’s income tax filings. Accordingly, management must determine the appropriate allocation of income to each of these jurisdictions based on current interpretations of complex income tax regulations. Income tax audits associated with the allocation of this income and other complex issues, including inventory transfer pricing and cost sharing, product royalty and foreign branch arrangements, may require an extended period of time to resolve and may result in significant income tax adjustments if changes to the income allocation are required between jurisdictions with different income tax rates.

Capital_Stock_and_Earnings_Per

Capital Stock and Earnings Per Share	6 Months Ended
	Jun. 29, 2014
Earnings Per Share [Abstract]	'
Capital Stock and Earnings Per Share	'
	10. Capital Stock and Earnings Per Share
	The Company had 48.8 million and 48.5 million ordinary shares issued and outstanding as of June 29, 2014 and December 29, 2013, respectively.
	The Company had options to purchase ordinary shares and RSUs outstanding of an aggregate 2.9 million and 3.2 million at June 29, 2014 and December 29, 2013, respectively. None of the options or RSUs were included in diluted earnings per share for the three months or six months ended June 29, 2014 and June 30, 2013 because the Company recorded a net loss in those periods; and therefore, including these instruments would be anti-dilutive.

Special_Charges

Special Charges	6 Months Ended
	Jun. 29, 2014
Text Block [Abstract]	'
Special Charges	'
	11. Special Charges
	Special charges are recorded as a separate line item within operating expenses on the consolidated statements of operations and primarily include operating expenses directly related to business combinations and related integration activities, restructuring initiatives, management exit costs and certain other items that are typically infrequent in nature and that affect the comparability and trend of operating results. The table below summarizes amounts included in special charges for the related periods:
		Six months ended
		June 29, 2014			June 30, 2013
	Acquisition, integration and distributor transition costs	$	2,036		$	3,713
	Legal Settlements		—			1,214
	OrthoHelix restructuring charges		1,011			—
	Other		325			—
	Total	$	3,372		$	4,927
	Included in special charges for the six months ended June 29, 2014 were $2.0 million of expenses related to U.S. distributor transitions and the integration of OrthoHelix and $1.0 million of OrthoHelix restructuring costs.
	Included in special charges for the six months ended June 30, 2013 was $3.7 million of expenses related to the Company’s acquisition and integration of OrthoHelix, U.S. distributor transitions, the Company’s acquisition of certain assets of its Canadian distributor and the Company’s acquisition of certain assets of a distributor in the United Kingdom. Additionally, the Company executed certain legal settlements in the second quarter of 2013, incurring additional charges of $1.2 million.
	OrthoHelix Restructuring Initiative
	In December 2013, as part of the on-going integration of OrthoHelix, the Company announced the move and consolidation of various business operations from Medina, Ohio to Bloomington, Minnesota, including customer service, quality, supply chain and finance functions.
	Included in accrued liabilities on the consolidated balance sheet as of June 29, 2014 is an accrual related to the OrthoHelix restructuring initiative. Activity in the restructuring accrual is presented in the following table (in thousands):
	OrthoHelix restructuring accrual balance as of December 29, 2013	$	381
	Charges:
	Employee termination benefits		483
	Moving, professional fees and other initiative-related expenses		528
	Total charges		1,011
	Payments:
	Employee termination benefits		(182	)
	Moving, professional fees and other initiative-related expenses		(526	)
	Total payments		(708	)
	OrthoHelix restructuring initiative accrual balance as of June 29, 2014	$	684

Litigation

Litigation	6 Months Ended
	Jun. 29, 2014
Commitments And Contingencies Disclosure [Abstract]	'
Litigation	'
	12. Litigation
	From time to time, the Company is subject to various pending or threatened legal actions and proceedings, including those that arise in the ordinary course of its business. These actions and proceedings may relate to, among other things, product liability, intellectual property, distributor, commercial and other matters. Such matters are subject to many uncertainties and to outcomes that are not predictable with assurance and that may not be known for extended periods of time. The Company records a liability in its consolidated financial statements for costs related to claims, including future legal costs, settlements and judgments, where the Company has assessed that a loss is probable and an amount can be reasonably estimated. If the reasonable estimate of a probable loss is a range, the Company records the most probable estimate of the loss or the minimum amount when no amount within the range is a better estimate than any other amount. The Company discloses a contingent liability even if the liability is not probable or the amount is not estimable, or both, if there is a reasonable possibility that a material loss may have been incurred. In the opinion of management, as of June 29, 2014, the amount of liability, if any, with respect to these matters, individually or in the aggregate, will not materially affect the Company’s consolidated results of operations, financial position or cash flows.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 29, 2014
Accounting Policies [Abstract]	'
Consolidation	'
	Consolidation
	The consolidated financial statements include the accounts of the Company and all of its wholly and majority owned subsidiaries. In consolidation, all material intercompany accounts and transactions are eliminated.
Use of Estimates	'
	Use of Estimates
	The consolidated financial statements are prepared in conformity with United States generally accepted accounting principles (U.S. GAAP) and include amounts that are based on management’s best estimates and judgments. Actual results could differ from those estimates.
Basis of Presentation	'
	Basis of Presentation
	The Company’s fiscal year-end is generally determined on a 52-week basis consisting of four 13-week quarters and always falls on the Sunday nearest to December 31.
	In the opinion of the Company’s management, the unaudited interim financial statements have been prepared on the same basis as the audited financial statements and include all adjustments, consisting of normal recurring accruals, necessary for the fair presentation of the Company’s interim results. The results of operations for any interim period are not indicative of results for the full fiscal year.
	All amounts are presented in U.S. Dollar (“$”), except where expressly stated as being in other currencies, e.g. Euros (“€”).
Seasonality	'
	Seasonality
	The Company’s business is somewhat seasonal in nature, as many of its products are used in elective procedures, which typically decline during the summer months and can increase at the end of the year once annual deductibles have been met on health insurance plans.
Recently Issued Accounting Pronouncements	'
	Recently Issued Accounting Pronouncements
	In July 2013, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2013-11, Income Taxes (ASC Topic 740), Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists. The ASU requires entities to present unrecognized tax benefits as a decrease in a net operating loss, similar to tax loss or tax credit carryforward if certain criteria are met. The standard clarifies presentation requirements for unrecognized tax benefits but will not alter the way in which entities assess deferred tax assets for realizability. The guidance is effective for the fiscal year, and interim periods within that fiscal year, beginning after December 15, 2013. The Company adopted this guidance beginning in the first quarter of 2014. The impact of adoption was not material.
	In March 2013, the FASB issued ASU 2013-05, Foreign Currency Matters (ASC Topic 830), Parent’s Accounting for the Cumulative Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity. The ASU requires entities to release cumulative translation adjustments to earnings when an entity ceases to have a controlling financial interest in a subsidiary or group of assets within a consolidated foreign entity and the sale or transfer results in the complete or substantially complete liquidation of the foreign entity. The ASU is effective for the fiscal year, and interim periods within that fiscal year, beginning after December 15, 2013 and is to be applied prospectively. The Company adopted this guidance in the first quarter of 2014. The impact of adoption was not material.
	In February 2013, the FASB issued ASU 2013-04, Liabilities (ASC Topic 405), Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation is Fixed at the Reporting Date. The ASU requires an entity that is jointly and severally liable to measure the obligation as the sum of the amount the entity has agreed with co-obligors to pay and any additional amount it expects to pay on behalf of one or more co-obligors. The amendment is effective for the fiscal year, and interim periods within that fiscal year, beginning after December 15, 2013 and should be applied retrospectively. The Company adopted this guidance beginning in the first quarter of 2014. The impact of adoption was not material.
	In April 2014, the FASB issued ASU 2014-08, Presentation of Financial Statements (ASC Topic 205) and Property, Plant, and Equipment (ASC Topic 360)—Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity. ASU 2014-08 provides new guidance related to the definition of a discontinued operation and requires new disclosures of both discontinued operations and certain other disposals that do not meet the definition of a discontinued operation. This new guidance is effective for annual periods beginning on or after December 15, 2014 and interim periods within those years. Beginning in 2015, the Company will adopt the new guidance, as applicable, to future disposals of components or classifications as held for sale.
	In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers issued as a new topic, ASC 606. ASU 2014-09 provides new guidance related to how an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, ASU 2014-08 specifies new accounting for costs associated with obtaining or fulfilling contracts with customers and expands the required disclosures related to revenue and cash flows from contracts with customers. This new guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016, and can be adopted either retrospectively to each prior reporting period presented or as a cumulative-effect adjustment as of the date of adoption, with early application not permitted. The Company is currently determining its implementation approach and assessing the impact on its consolidated financial statements and related disclosures.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	The Company applies ASC Topic 820, which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. The Company measures certain assets and liabilities at fair value on a recurring or non-recurring basis. U.S. GAAP requires fair value measurements to be classified and disclosed in one of the following three categories:
	Level 1—Assets and liabilities with unadjusted, quoted prices listed on active market exchanges.
	Level 2—Assets and liabilities determined using prices for recently traded assets and liabilities with similar underlying terms, as well as directly or indirectly observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.
	Level 3—Assets and liabilities that are not actively traded on a market exchange. This category includes situations where there is little, if any, market activity for the asset or liability. The prices are determined using significant unobservable inputs or valuation techniques.
	A summary of the financial assets and liabilities that are measured at fair value on a recurring basis at June 29, 2014 and December 29, 2013 are as follows:
		June 29, 2014			Quoted Prices in		Significant		Significant
					Active Markets		Other		Unobservable
					(Level 1)		Observable		Inputs (Level 3)
							Inputs (Level 2)
	Cash and cash equivalents	$	31,771		$	31,771	$	—	$	—
	Contingent consideration		(8,815	)		—		—		(8,815	)
	Derivative assets		89			—		89		—
	Total, net	$	23,045		$	31,771	$	89	$	(8,815	)
		December 29, 2013			Quoted Prices in		Significant		Significant
					Active Markets		Other		Unobservable
					(Level 1)		Observable		Inputs (Level 3)
							Inputs (Level 2)
	Cash and cash equivalents	$	56,784		$	56,784	$	—	$	—
	Contingent consideration		(12,956	)		—		—		(12,956	)
	Derivative assets		238			—		238		—
	Total, net	$	44,066		$	56,784	$	238	$	(12,956	)
	As of June 29, 2014 and December 29, 2013, the Company had derivative assets with fair values of $0.1 million and $0.2 million, respectively, with recurring Level 2 fair value measurements. The derivatives are foreign exchange forward contracts and their fair values are based on pricing for similar recently executed transactions. The amount of gain recognized in foreign currency transaction loss for the six months ended June 29, 2014 and June 30, 2013 related to these derivatives is $0.2 million and $0.1 million, respectively.
	Included in Level 3 fair value measurements as of June 29, 2014 is a $5.9 million contingent consideration liability related to potential earn-out payments for the acquisition of OrthoHelix Surgical Designs, Inc. (OrthoHelix) that was completed in October 2012, a $2.3 million contingent consideration liability related to potential earn-out payments for distributor acquisitions in the United States that occurred throughout 2013 and the first six months of 2014, a $0.4 million contingent consideration liability related to potential earn-out payments for the acquisition of the Company’s exclusive distributor in Belgium and Luxembourg that was completed in May 2012, and a $0.2 million contingent consideration liability related to potential earn-out payments related to the acquisition of a distributor in Australia that was completed in 2013. Contingent consideration liabilities are carried at fair value and are included in contingent consideration (short-term and long-term) on the consolidated balance sheets. The contingent consideration liabilities were determined based on discounted cash flow analyses that included revenue estimates and a discount rate, which are considered significant unobservable inputs as of June 29, 2014. The revenue estimates were based on current management expectations for these businesses and the discount rate used was between 8-11% and was based on the Company’s estimated weighted average cost of capital as adjusted for each transaction. To the extent that these assumptions were to change, the fair value of the contingent consideration liabilities could change significantly. Included in interest expense on the consolidated statements of operations for the six months ended June 29, 2014 and June 30, 2013 is $0.3 million and $0.6 million, respectively, related to the accretion of the contingent consideration. There were no transfers between levels during the periods presented.
	Included in Level 3 fair value measurements as of December 29, 2013 is a $10.4 million contingent consideration liability related to potential earnout payments for the acquisition of OrthoHelix that was completed in October 2012, a $1.9 million contingent consideration liability related to potential earn-out payments for distributor acquisitions in the United States that occurred throughout 2013, a $0.5 million contingent consideration liability related to potential earnout payments for the acquisition of the Company’s exclusive distributor in Belgium and Luxembourg that was completed in May 2012 and a $0.2 million contingent consideration liability related to potential earnout payments related to the acquisition of a distributor in Australia that was completed in 2013.
	A rollforward of the Level 3 contingent consideration liabilities, both short and long-term, for the six months ended June 29, 2014 is as follows (in thousands):
	Contingent consideration liability at December 29, 2013	$	12,956
	Additions		1,670
	Fair value adjustments		(312	)
	Settlements		(5,802	)
	Interest accretion		299
	Foreign currency translation		4
	Contingent consideration liability at June 29, 2014	$	8,815
	The Company also has certain assets and liabilities that are measured at fair value on a non-recurring basis. The Company reviews the carrying amount of its long-lived assets other than goodwill for potential impairment whenever events or changes in circumstances indicate that their carrying values may not be recoverable. During the six months ended June 29, 2014 and June 30, 2013, the Company recognized no impairments. During 2013, the Company initiated and completed a facilities consolidation initiative that included the termination of certain facility leases. The termination liability for these leases was determined using a discounted cash flow analysis that included a discount rate assumption, which is based on the credit adjusted risk free interest rate input, and an assumption related to the timing and amount of sublease income. The timing of the sublease income is a significant unobservable input and thus is considered a Level 3 fair value measurement. As of June 29, 2014, the value of this liability was $0.3 million.
	As of June 29, 2014 and December 29, 2013, the Company had short-term and long-term debt of $69.3 million and $69.1 million, respectively, the vast majority of which was variable rate debt. The fair value of the Company’s debt obligations approximates carrying value as a result of its variable rate term and is considered a Level 2 fair value measurement.

Fair_Value_of_Financial_Instru1

Fair Value of Financial Instruments (Tables)	6 Months Ended
	Jun. 29, 2014
Fair Value Disclosures [Abstract]	'
Summary of Financial Assets and Liabilities Measured at Fair Value	'
	A summary of the financial assets and liabilities that are measured at fair value on a recurring basis at June 29, 2014 and December 29, 2013 are as follows:
		June 29, 2014			Quoted Prices in		Significant		Significant
					Active Markets		Other		Unobservable
					(Level 1)		Observable		Inputs (Level 3)
							Inputs (Level 2)
	Cash and cash equivalents	$	31,771		$	31,771	$	—	$	—
	Contingent consideration		(8,815	)		—		—		(8,815	)
	Derivative assets		89			—		89		—
	Total, net	$	23,045		$	31,771	$	89	$	(8,815	)
		December 29, 2013			Quoted Prices in		Significant		Significant
					Active Markets		Other		Unobservable
					(Level 1)		Observable		Inputs (Level 3)
							Inputs (Level 2)
	Cash and cash equivalents	$	56,784		$	56,784	$	—	$	—
	Contingent consideration		(12,956	)		—		—		(12,956	)
	Derivative assets		238			—		238		—
	Total, net	$	44,066		$	56,784	$	238	$	(12,956	)
Summary of Contingent Consideration Liabilities, Both Short and Long-term	'
	A rollforward of the Level 3 contingent consideration liabilities, both short and long-term, for the six months ended June 29, 2014 is as follows (in thousands):
	Contingent consideration liability at December 29, 2013	$	12,956
	Additions		1,670
	Fair value adjustments		(312	)
	Settlements		(5,802	)
	Interest accretion		299
	Foreign currency translation		4
	Contingent consideration liability at June 29, 2014	$	8,815

Inventories_Tables

Inventories (Tables)	6 Months Ended
	Jun. 29, 2014
Inventory Disclosure [Abstract]	'
Inventory Balances	'
	Inventory balances consist of the following (in thousands):
		June 29, 2014		December 29, 2013
	Raw materials	$	7,007	$	6,840
	Work-in-process		13,154		9,171
	Finished goods		75,399		71,000
	Total	$	95,560	$	87,011

Property_Plant_and_Equipment_T

Property, Plant and Equipment (Tables)	6 Months Ended
	Jun. 29, 2014
Property Plant And Equipment [Abstract]	'
Property, Plant and Equipment Balances	'
	Property, plant and equipment balances consist of the following (in thousands):
		June 29,			December 29,
		2014			2013
	Land	$	1,651		$	1,886
	Building and improvements		13,646			14,255
	Machinery and equipment		31,771			31,192
	Furniture, fixtures and office equipment		30,522			29,371
	Software		5,399			5,511
	Construction in progress		7,454			5,628
	Property, plant and equipment, gross		90,443			87,843
	Accumulated depreciation		(46,024	)		(44,349	)
	Property, plant and equipment, net	$	44,419		$	43,494

Instruments_Tables

Instruments (Tables)	6 Months Ended
	Jun. 29, 2014
Text Block [Abstract]	'
Instruments Included in Long-Term Assets	'
	Instruments are included in long-term assets on the consolidated balance sheets and consist of the following (in thousands):
		June 29,			December 29,
		2014			2013
	Instruments	$	109,022		$	99,754
	Instruments in process		27,108			23,990
	Accumulated depreciation		(67,187	)		(60,689	)
	Instruments, net	$	68,943		$	63,055

Goodwill_and_Other_Intangible_1

Goodwill and Other Intangible Assets (Tables)	6 Months Ended
	Jun. 29, 2014
Goodwill And Intangible Assets Disclosure [Abstract]	'
Changes in Carrying Amount of Goodwill	'
	The following table summarizes the changes in the carrying amount of goodwill (in thousands):
	Balance at December 29, 2013	$	251,540
	Goodwill additions as a result of acquisitions		2,467
	Foreign currency translation		(1,033	)
	Balance at June 29, 2014	$	252,974
Components of Identifiable Intangible Assets	'
	The components of identifiable intangible assets are as follows (in thousands):
		Gross value			Accumulated			Net value
					amortization
	Balances at June 29, 2014
	Intangible assets subject to amortization:
	Developed technology	$	112,657		$	(48,604	)	$	64,053
	Customer relationships		61,085			(32,126	)		28,959
	Licenses		6,831			(4,601	)		2,230
	Other		7,109			(3,455	)		3,654
	Intangible assets not subject to amortization:
	Trade name		9,824			—			9,824
	Total	$	197,506		$	(88,786	)	$	108,720
		Gross value			Accumulated			Net value
					amortization
	Balances at December 29, 2013
	Intangible assets subject to amortization:
	Developed technology	$	112,782		$	(44,161	)	$	68,621
	Customer relationships		61,783			(30,155	)		31,628
	Licenses		6,810			(4,004	)		2,806
	In-process research and development		400			—			400
	Other		6,624			(2,431	)		4,193
	Intangible assets not subject to amortization:
	Trade name		9,960			—			9,960
	Total	$	198,359		$	(80,751	)	$	117,608
Estimated Annual Amortization Expense	'
	Estimated annual amortization expense for fiscal years ending 2014 through 2018 is as follows (in thousands):
		Amortization expense
	2014	$	17,411
	2015		16,819
	2016		14,479
	2017		13,470
	2018		12,646

ShareBased_Compensation_Tables

Share-Based Compensation (Tables)	6 Months Ended
	Jun. 29, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Summary of Allocation of Share-Based Compensation	'
	Below is a summary of the allocation of share-based compensation (in thousands):
		Three months ended					Six months ended
		June 29,			June 30,		June 29,		June 30,
		2014			2013		2014		2013
					(unaudited)				(unaudited)
	Cost of goods sold	$	152		$	120	$	304	$	264
	Selling, general and administrative		2,341			1,180		3,900		2,525
	Research and development		249			136		317		280
	Total	$	2,742		$	1,436	$	4,521	$	3,069
Share-Based Compensation Weighted-Average Assumptions	'
	The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model using the following weighted-average assumptions:
		Six months ended
		June 29, 2014
	Risk-free interest rate		1.9	%
	Expected life in years		6
	Expected volatility		45	%
	Expected dividend yield		0	%

Special_Charges_Tables

Special Charges (Tables)	6 Months Ended
	Jun. 29, 2014
Text Block [Abstract]	'
Schedule of Special Charges	'
	The table below summarizes amounts included in special charges for the related periods:
		Six months ended
		June 29, 2014			June 30, 2013
	Acquisition, integration and distributor transition costs	$	2,036		$	3,713
	Legal Settlements		—			1,214
	OrthoHelix restructuring charges		1,011			—
	Other		325			—
	Total	$	3,372		$	4,927
Activity in Restructuring Accrual	'
	Activity in the restructuring accrual is presented in the following table (in thousands):
	OrthoHelix restructuring accrual balance as of December 29, 2013	$	381
	Charges:
	Employee termination benefits		483
	Moving, professional fees and other initiative-related expenses		528
	Total charges		1,011
	Payments:
	Employee termination benefits		(182	)
	Moving, professional fees and other initiative-related expenses		(526	)
	Total payments		(708	)
	OrthoHelix restructuring initiative accrual balance as of June 29, 2014	$	684

Fair_Value_of_Financial_Instru2

Fair Value of Financial Instruments - Summary of Financial Assets and Liabilities Measured at Fair Value (Detail) (USD $)	Jun. 29, 2014	Dec. 29, 2013	Jun. 30, 2013	Dec. 30, 2012
In Thousands, unless otherwise specified
Fair Value Assets Liabilities Measured On Recurring Basis [Line Items]	'	'	'	'
Cash and cash equivalents	$31,771	$56,784	$58,715	$31,108
Fair Value, Measurements, Recurring [Member]	'	'	'	'
Fair Value Assets Liabilities Measured On Recurring Basis [Line Items]	'	'	'	'
Cash and cash equivalents	31,771	56,784	'	'
Contingent consideration	-8,815	-12,956	'	'
Derivative assets	89	238	'	'
Total, net	23,045	44,066	'	'
Quoted Prices in Active Markets (Level 1) [Member] | Fair Value, Measurements, Recurring [Member]	'	'	'	'
Fair Value Assets Liabilities Measured On Recurring Basis [Line Items]	'	'	'	'
Cash and cash equivalents	31,771	56,784	'	'
Contingent consideration	'	'	'	'
Derivative assets	'	'	'	'
Total, net	31,771	56,784	'	'
Significant Other Observable Inputs (Level 2) [Member] | Fair Value, Measurements, Recurring [Member]	'	'	'	'
Fair Value Assets Liabilities Measured On Recurring Basis [Line Items]	'	'	'	'
Cash and cash equivalents	'	'	'	'
Contingent consideration	'	'	'	'
Derivative assets	89	238	'	'
Total, net	89	238	'	'
Significant Unobservable Inputs (Level 3) [Member] | Fair Value, Measurements, Recurring [Member]	'	'	'	'
Fair Value Assets Liabilities Measured On Recurring Basis [Line Items]	'	'	'	'
Cash and cash equivalents	'	'	'	'
Contingent consideration	-8,815	-12,956	'	'
Derivative assets	'	'	'	'
Total, net	($8,815)	($12,956)	'	'

Fair_Value_of_Financial_Instru3

Fair Value of Financial Instruments - Additional Information (Detail) (USD $)

6 Months Ended

6 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

In Millions, unless otherwise specified

Jun. 29, 2014

Jun. 30, 2013

Dec. 29, 2013

Jun. 29, 2014

Jun. 29, 2014

Jun. 29, 2014

Jun. 30, 2013

Dec. 29, 2013

Jun. 29, 2014

Dec. 29, 2013

Jun. 29, 2014

Dec. 29, 2013

Jun. 29, 2014

Dec. 29, 2013

Jun. 29, 2014

Dec. 29, 2013

Minimum [Member]

Maximum [Member]

Significant Other Observable Inputs (Level 2) [Member]

Significant Other Observable Inputs (Level 2) [Member]

Significant Other Observable Inputs (Level 2) [Member]

OrthoHelix [Member]

OrthoHelix [Member]

Distributor in Belgium and Luxembourg [Member]

Distributor in Belgium and Luxembourg [Member]

Distributor in the United States [Member]

Distributor in the United States [Member]

Distributor in Australia [Member]

Distributor in Australia [Member]

Significant Unobservable Inputs (Level 3) [Member]

Significant Unobservable Inputs (Level 3) [Member]

Significant Unobservable Inputs (Level 3) [Member]

Significant Unobservable Inputs (Level 3) [Member]

Significant Unobservable Inputs (Level 3) [Member]

Significant Unobservable Inputs (Level 3) [Member]

Significant Unobservable Inputs (Level 3) [Member]

Significant Unobservable Inputs (Level 3) [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of Derivative asset

'

'

'

'

'

$0.10

'

$0.20

'

'

'

'

'

'

'

'

Foreign currency transaction gain (loss) related to derivatives

'

'

'

'

'

0.2

0.1

'

'

'

'

'

'

'

'

'

Contingent consideration related to acquisition

'

'

'

'

'

'

'

'

5.9

10.4

0.4

0.5

2.3

1.9

0.2

0.2

Discount rate, Percentage

'

'

'

8.00%

11.00%

'

'

'

'

'

'

'

'

'

'

'

Interest expense on the accretion of the contingent consideration

0.3

0.6

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Transfers between levels

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Intangible impairment

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Sublease termination liability

0.3

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Short-term and long term debt

$69.30

'

$69.10

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair_Value_of_Financial_Instru4

Fair Value of Financial Instruments - Summary of Contingent Consideration Liabilities, Both Short and Long-term (Detail) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 29, 2014
Debt Instrument Fair Value Carrying Value [Abstract]	'
Contingent consideration liability at December 29, 2013	$12,956
Additions	1,670
Fair value adjustments	-312
Settlements	-5,802
Interest accretion	299
Foreign currency translation	4
Contingent consideration liability at June 29, 2014	$8,815

Inventories_Inventory_Balances

Inventories - Inventory Balances (Detail) (USD $)	Jun. 29, 2014	Dec. 29, 2013
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Raw materials	$7,007	$6,840
Work-in-process	13,154	9,171
Finished goods	75,399	71,000
Total	$95,560	$87,011

Property_Plant_and_Equipment_P

Property, Plant and Equipment - Property, Plant and Equipment Balances (Detail) (USD $)	Jun. 29, 2014	Dec. 29, 2013
In Thousands, unless otherwise specified
Property Plant And Equipment Useful Life And Values [Abstract]	'	'
Land	$1,651	$1,886
Building and improvements	13,646	14,255
Machinery and equipment	31,771	31,192
Furniture, fixtures and office equipment	30,522	29,371
Software	5,399	5,511
Construction in progress	7,454	5,628
Property, plant and equipment, gross	90,443	87,843
Accumulated depreciation	-46,024	-44,349
Property, plant and equipment, net	$44,419	$43,494

Instruments_Instruments_Includ

Instruments - Instruments Included in Long-Term Assets (Detail) (USD $)	Jun. 29, 2014	Dec. 29, 2013
In Thousands, unless otherwise specified
Offsetting [Abstract]	'	'
Instruments	$109,022	$99,754
Instruments in process	27,108	23,990
Accumulated depreciation	-67,187	-60,689
Instruments, net	$68,943	$63,055

Goodwill_and_Other_Intangible_2

Goodwill and Other Intangible Assets - Changes in Carrying Amount of Goodwill (Detail) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 29, 2014
Goodwill And Intangible Assets Disclosure [Abstract]	'
Goodwill, Beginning balance	$251,540
Goodwill additions as a result of acquisitions	2,467
Foreign currency translation	-1,033
Goodwill, Ending balance	$252,974

Goodwill_and_Other_Intangible_3

Goodwill and Other Intangible Assets - Components of Identifiable Intangible Assets (Detail) (USD $)	Jun. 29, 2014	Dec. 29, 2013
In Thousands, unless otherwise specified
Goodwill And Other Intangible Assets [Line Items]	'	'
Gross value	$197,506	$198,359
Accumulated amortization	-88,786	-80,751
Net value	108,720	117,608
Developed technology [Member]	'	'
Goodwill And Other Intangible Assets [Line Items]	'	'
Gross value	112,657	112,782
Accumulated amortization	-48,604	-44,161
Net value	64,053	68,621
Customer relationships [Member]	'	'
Goodwill And Other Intangible Assets [Line Items]	'	'
Gross value	61,085	61,783
Accumulated amortization	-32,126	-30,155
Net value	28,959	31,628
Licenses [Member]	'	'
Goodwill And Other Intangible Assets [Line Items]	'	'
Gross value	6,831	6,810
Accumulated amortization	-4,601	-4,004
Net value	2,230	2,806
In-process research and development [Member]	'	'
Goodwill And Other Intangible Assets [Line Items]	'	'
Gross value	'	400
Accumulated amortization	'	'
Net value	'	400
Other [Member]	'	'
Goodwill And Other Intangible Assets [Line Items]	'	'
Gross value	7,109	6,624
Accumulated amortization	-3,455	-2,431
Net value	3,654	4,193
Trade name [Member]	'	'
Goodwill And Other Intangible Assets [Line Items]	'	'
Gross value	9,824	9,960
Accumulated amortization	'	'
Net value	$9,824	$9,960

Goodwill_and_Other_Intangible_4

Goodwill and Other Intangible Assets - Estimated Annual Amortization Expense (Detail) (USD $)	Jun. 29, 2014
In Thousands, unless otherwise specified
Goodwill And Intangible Assets Disclosure [Abstract]	'
2014	$17,411
2015	16,819
2016	14,479
2017	13,470
2018	$12,646

Goodwill_and_Other_Intangible_5

Goodwill and Other Intangible Assets - Additional Information (Detail) (USD $)	6 Months Ended
	Jun. 29, 2014
Goodwill And Intangible Assets [Line Items]	'
Goodwill acquired	$2,467,000
United States [Member]	'
Goodwill And Intangible Assets [Line Items]	'
Goodwill acquired	2,500,000
United States [Member] | Non Compete Agreement [Member]	'
Goodwill And Intangible Assets [Line Items]	'
Intangible assets acquired	$200,000

ShareBased_Compensation_Additi

Share-Based Compensation - Additional Information (Detail) (USD $)	6 Months Ended
	Jun. 29, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Service period	'4 years
Options expire period	'10 years
Granted options to purchase ordinary shares	20,661
Weighted average exercise price per share	$19.66
Weighted average fair value per share	$8.74
Maximum [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Share-based awards granted under Tornier N.V.2010 Incentive Plan	7,700,000
Restricted stock units [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Restricted stock unit, Granted	20,834
Weighted-average grant date fair value, Granted	$19.42
Performance accelerated restricted stock units (PARS) [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Weighted average fair value per share	$19.24
Restricted stock unit, Granted	100,000
Vesting period of performance accelerated restricted stock units	'3 years 4 months 24 days
Performance accelerated restricted stock units (PARS) [Member] | Performance Based Restricted Stock Units Vesting After Two Years [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Graded service-based vesting rate of performance accelerated restricted stock units	50.00%
Performance accelerated restricted stock units (PARS) [Member] | Performance Based Restricted Stock Units Vesting After Third Year [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Graded service-based vesting rate of performance accelerated restricted stock units	25.00%
Performance accelerated restricted stock units (PARS) [Member] | Performance Based Restricted Stock Units Vesting After Fourth Year [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Graded service-based vesting rate of performance accelerated restricted stock units	25.00%

ShareBased_Compensation_Summar

Share-Based Compensation - Summary of Allocation of Share-Based Compensation (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 29, 2014	Jun. 30, 2013	Jun. 29, 2014	Jun. 30, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Allocated share-based compensation expense	$2,742	$1,436	$4,521	$3,069
Cost of goods sold [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Allocated share-based compensation expense	152	120	304	264
Selling, general and administrative [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Allocated share-based compensation expense	2,341	1,180	3,900	2,525
Research and development [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Allocated share-based compensation expense	$249	$136	$317	$280

ShareBased_Compensation_ShareB

Share-Based Compensation - Share-Based Compensation Weighted-Average Assumptions (Detail)	6 Months Ended
	Jun. 29, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Risk-free interest rate	1.90%
Expected life in years	'6 years
Expected volatility	45.00%
Expected dividend yield	0.00%

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended
	Jun. 29, 2014	Jun. 30, 2013	Jun. 29, 2014	Jun. 30, 2013
Reconciliation Of Unrecognized Tax Benefits [Line Items]	'	'	'	'
Pre-tax losses	($9,487,000)	($12,117,000)	($15,624,000)	($18,973,000)
Income tax expense	961,000	420,000	61,000	462,000
Additional tax benefit from reversal of reserve for uncertain tax positions	500,000	'	500,000	'
Maximum [Member]	'	'	'	'
Reconciliation Of Unrecognized Tax Benefits [Line Items]	'	'	'	'
Effective tax rate	'	'	0.10%	'
European Jurisdiction [Member]	'	'	'	'
Reconciliation Of Unrecognized Tax Benefits [Line Items]	'	'	'	'
Income tax expense	'	'	$600,000	'

Capital_Stock_and_Earnings_Per1

Capital Stock and Earnings Per Share - Additional Information (Detail)	3 Months Ended		6 Months Ended
	Jun. 29, 2014	Jun. 30, 2013	Jun. 29, 2014	Jun. 30, 2013	Dec. 29, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'	'	'	'	'
Ordinary shares, issued	48,797,382	'	48,797,382	'	48,508,612
Ordinary shares, outstanding	48,797,382	'	48,797,382	'	48,508,612
Aggregate outstanding options and restricted stock units	2,900,000	'	2,900,000	'	3,200,000
Options included in dilutive earnings per share	0	0	0	0	'

Special_Charges_Schedule_of_Sp

Special Charges - Schedule of Special Charges (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 29, 2014	Jun. 30, 2013	Jun. 29, 2014	Jun. 30, 2013
Special Charges [Line Items]	'	'	'	'
Acquisition, integration and distributor transition costs	'	'	$2,036	$3,713
Legal Settlements	'	'	'	1,214
Other	'	'	325	'
Total	686	3,408	3,372	4,927
OrthoHelix [Member]	'	'	'	'
Special Charges [Line Items]	'	'	'	'
Restructuring charges	'	'	$1,011	'

Special_Charges_Additional_Inf

Special Charges - Additional Information (Detail) (USD $)	3 Months Ended	6 Months Ended
	Jun. 30, 2013	Jun. 30, 2013	Jun. 29, 2014
			OrthoHelix [Member]
Special Charges [Line Items]	'	'	'
Acquisition and Integration cost	'	$3,700,000	$2,000,000
Restructuring related cost	'	'	1,011,000
Legal charges	$1,200,000	'	'

Special_Charges_Activity_in_Re

Special Charges - Activity in Restructuring Accrual (Detail) (OrthoHelix restructuring initiative [Member], USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 29, 2014
Restructuring Cost and Reserve [Line Items]	'
OrthoHelix restructuring accrual, beginning balance	$381
Restructuring charges	1,011
Payments for restructuring	-708
OrthoHelix restructuring initiative accrual, ending balance	684
Employee termination benefits [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Restructuring charges	483
Payments for restructuring	-182
Moving, professional fees and other initiative-related expenses [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Restructuring charges	528
Payments for restructuring	($526)